

## World-renowned pioneer in RNA therapeutics becomes Chief Scientific Officer at PYC Therapeutics

### Highlights

- PYC has appointed Sue Fletcher to the role of Chief Scientific Officer, a significant expansion of her time and scope within the Company.
- Sue is an internationally recognised pioneer in the field of RNA therapeutics, having co-invented multiple drugs that are now in market with others in late stage clinical development.
- Sue will lead PYC's efforts to discover and develop a pipeline of therapeutics for patients suffering from genetic disease.

### Announcement

PYC Therapeutics, (ASX: PYC) ('The Company' or 'PYC') is pleased to announce the appointment of Sue Fletcher, Ph.D. as Chief Scientific Officer (CSO). Sue has been working with PYC since 2019 and will now join the Company to lead the discovery and development of treatments for genetic disorders.

Sue brings over 25 years of experience in RNA therapeutics and is internationally recognised as a pioneer in the field. As co-inventor, her work led to the development of Eteplirsen (ExonDys51<sup>®</sup>), which was licensed to Sarepta Therapeutics and became the first FDA-approved drug specifically for Duchenne Muscular Dystrophy (DMD). Sue is also the co-inventor of Vyondys-53 (previously Golodirsen), which was approved by the FDA in 2019, and Casimersen, which has been submitted for FDA approval.

Sue has been responsible for PYC's lead program targeting a form of Retinitis Pigmentosa.

Sue is a Senior Principal Research Fellow at Murdoch University and an Adjunct Professor and lecturer at the University of Western Australia, both in Perth, Australia. She obtained a BSc in Zoology and Chemistry at the University of Zimbabwe and a PhD in Physiology at the University of Western Australia.

### Comments

Alan Tribe, PYC Chairman: *'Sue has been an integral part of PYC's transformation into an RNA therapeutics company. As CSO, she will be able to devote even more energy towards the development of novel therapeutics like our lead program. We are thrilled to have her leadership and expertise within PYC, and we are excited about the potential applications of our technology.'*

Sue Fletcher, PYC's CSO: *'I am very excited to expand my involvement with PYC. The development of our lead program and broader retinal pipeline has been incredibly rewarding. I look forward to leading the advancement of our retinal programs in parallel to expanding our approach to the central nervous system, where I believe our technology can have life-changing impact for patients.'*

*This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited*

**ENDS** For further information, please contact:



**INVESTORS**  
Kaggen Ausma  
CBO  
info@pyctx.com

### **About PYC Therapeutics**

*PYC Therapeutics (ASX: PYC) is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell Penetrating Peptides (CPPs) can overcome ‘the delivery challenge’ and provide access for a wide range of potent and precise drug ‘cargoes’ to the ‘undruggable genome’ – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.*

### **About Vision Pharma**

*Vision Pharma Pty Ltd (Vision) is a joint venture between PYC Therapeutics (PYC) and the Lions Eye Institute (LEI) dedicated to the development of new treatments for a range of debilitating eye diseases. Vision is advancing a lead program for the treatment of a form of Retinitis Pigmentosa as well as a range of other precision medicines for different eye diseases. Vision combines the clinical expertise of LEI with the drug development capabilities of PYC and is owned according to a 90% (PYC) and 10% (LEI) shareholding distribution.*

### **Forward looking statements**

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

---

Tel: +61 8 6151 0994

[pyctx.com](http://pyctx.com)

**PYC Therapeutics Limited**

ACN 098 391 961